InvestorsObserver
×
News Home

Where Does Aquestive Therapeutics Inc (AQST) Stock Fall in the Biotechnology Field?

Friday, June 26, 2020 11:04 AM | InvestorsObserver Analysts

Mentioned in this article

Where Does Aquestive Therapeutics Inc (AQST) Stock Fall in the Biotechnology Field?

Aquestive Therapeutics Inc (AQST) is near the top in its industry group according to InvestorsObserver. AQST gets an overall rating of 77. That means it scores higher than 77 percent of stocks. Aquestive Therapeutics Inc gets a 86 rank in the Biotechnology industry. Biotechnology is number 11 out of 148 industries.

Overall Score - 77
AQST has an Overall Score of 77. Find out what this means to you and get the rest of the rankings on AQST!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 77 would rank higher than 77 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Aquestive Therapeutics Inc Stock Today?

Aquestive Therapeutics Inc (AQST) stock is trading at $5.10 as of 11:00 AM on Friday, Jun 26, a decline of -$0.24, or -4.49% from the previous closing price of $5.34. The stock has traded between $4.96 and $5.26 so far today. Volume today is below average. So far 271,578 shares have traded compared to average volume of 1,272,193 shares.

To see the top 5 stocks in Biotechnology click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App